Skip to main content
. Author manuscript; available in PMC: 2010 Nov 15.
Published in final edited form as: Clin Cancer Res. 2009 Nov 10;15(22):7061–7068. doi: 10.1158/1078-0432.CCR-09-1241

Figure 2.

Figure 2

Figure 2

Figure 2a. Waterfall plot showing best response (by RECIST) of patients with thyroid cancer who reached their first restaging evaluation. All five of the MTC patients with available paraffin blocks had RET kinase mutations of exon 11. These mutations locate in the extracellular cysteine rich domain, which can cause ligand independent homodimerization and constitutive activation of the RET kinase.

Figure 2b. Best percent change in calcitonin and CEA levels from baseline in the six patients with medullary thyroid cancer who reached their first restaging. All six patients had a rapid decline in their calcitonin levels, and all patients except patient #2 had a significant decrease in CEA levels.